Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 10, 2026
Stryker Corp (SYK)
A forensic read on Stryker Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
B · Sound & dependable
Forensic grade
Safe
Financial health
8.5
Distress distance
Clean
Earnings quality
4
Forensic signals
38.8
P / E (ttm)
14.5%
ROE
$131.8B
Market cap
1.04%
Dividend yield
11.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Stryker Corp earns a B (Sound & dependable) forensic quality grade, and its balance-sheet distress test reads 8.5, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+11.4%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +11.4% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building faster than is comfortable — part of profit is sitting in the balance sheet rather than turning to cash. The build is led by inventory up +11% against +11% in cost of sales. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 6% of net operating assets, diverging from the balance-sheet accrual read.
9.5%
FY2025
Return on invested capital.Return on invested capital is 9.5% in the latest fiscal year and steady — around its ~10% cost of capital, so growth is roughly value-neutral.
+0.4%/yr
FY2022–FY2025
Share count.Diluted share count changed +1% over the last 3 years to FY2025 (+0.4%/yr). Roughly flat — the count is neither shrinking nor growing meaningfully. Per-share value isn't being meaningfully helped or hurt by the count.
$672M
FY2022–FY2024
Goodwill impairments.Took $672M of goodwill writedowns across 2 years (FY2022 ($216M), FY2024 ($456M)) — about 8% of net income over the span. Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$25.12B
Revenue Growth YoY+11.2%
Revenue CAGR (3yr)+10.8%
Net Margin12.9%
Free Cash Flow$4.28B
Return on Equity14.5%
Debt / Equity0.71x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Stryker Corp's actual 10-K/10-Q/8-K filings?